Search

Displaying results 3841 - 3850 of 10000 in total
  1. Drug

    Bopindolol

    go.drugbank.com/drugs/DB08807
    Experimental

    Bopindolol (INN) is an ester prodrug for the beta blocker [pindolol].

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  2. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

    Synonyms: Sn MesoporphyrinCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More Rings
  3. Drug

    Clonazoline

    go.drugbank.com/drugs/DB15881
    Experimental

    Clonazoline is

  4. Drug

    Caldaret

    go.drugbank.com/drugs/DB06231
    Investigational

    Categories: Heterocyclic Compounds, 1-Ring
  5. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    (completed for type 1 diabetes), and NCT05581043 (completed for type 2 diabetes). … Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236

    Synonyms: 3-HYDROXYBUTYRIC ACID, 3-HYDROXY-BUTANOIC ACID
  6. Drug

    NCX 1022

    go.drugbank.com/drugs/DB05410
    Experimental

    NCX is an NO-releasing derivative of hydrocortisone.

  7. Drug

    Taribavirin

    go.drugbank.com/drugs/DB06408
    Investigational

  8. Drug

    Oxomemazine

    go.drugbank.com/drugs/DB13820
    Investigational

    Oxomemazine is a phenothiazine derivative.

    Categories: Heterocyclic Compounds, 3-Ring
  9. Drug

    Zansecimab

    go.drugbank.com/drugs/DB16389
    Investigational

    Zansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).

  10. Drug

    PR-15

    go.drugbank.com/drugs/DB06037
    Investigational

    PR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.